Literature DB >> 6481248

High performance liquid chromatography of platelet-activating factors.

E M Jackson, G E Mott, C Hoppens, L M McManus, S T Weintraub, J C Ludwig, R N Pinckard.   

Abstract

Silica and C18 reverse phase high performance liquid chromatography (HPLC) were used to fractionate synthetic molecular species of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC) and semi-synthetic platelet-activating factor (PAF) synthesized from beef heart plasmalogens. A single coincident peak from silica HPLC was observed for either a mixture of synthetic AGEPC's with alkyl chain lengths from C12 to C18 or for beef heart-derived PAF. This peak was well separated from other classes of phospholipid standards including 2-lysophosphatidylcholine and 3H-labeled lyso-PAF. Subsequently, the synthetic AGEPC mixture or beef heart PAF was separated into individual species on a C18 reverse phase column. Beef heart-derived PAF was fractionated into at least four molecular species of PAF activity which had similar retention times as the radioactivity of 3H-labeled beef heart PAF. Approximately 56% of the radioactivity of 3H-labeled PAF was found in the fraction with a similar retention time as 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine, 10% as 1-O-octadecyl-2-acetyl-sn-glycero-3-phosphocholine, 11% as 1-O-pentadecyl-2-acetyl-sn-glycero-3-phosphocholine, and 13% in an unidentified fraction which eluted after C-16-AGEPC. The unidentified fraction did not correspond to any of the homologous series of synthetic AGEPCs with saturated alkyl chain lengths from C12 to C18. Recoveries of radioactive phospholipids from silica or reverse phase columns were greater than 95%.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6481248

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage.

Authors:  T R Martin; G Raugi; T L Merritt; W R Henderson
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

2.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.

Authors:  A J Wardlaw; R Moqbel; O Cromwell; A B Kay
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

3.  Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis.

Authors:  J L Macpherson; A Kemp; M Rogers; A I Mallet; R F Toia; B Spur; J W Earl; C N Chesterman; S A Krilis
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

4.  Biosynthesis of platelet-activating factor in glandular gastric mucosa. Evidence for the involvement of the 'de novo' pathway and modulation by fatty acids.

Authors:  S Fernandez-Gallardo; M A Gijon; M C Garcia; E Cano; M Sanchez Crespo
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

5.  Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

Authors:  F Lopez Diez; M L Nieto; S Fernandez-Gallardo; M A Gijon; M Sanchez Crespo
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.